Pharmaceutical

FDA clears Krystal Biotech’s IND for Type 1 AATD treatment KB408

A Phase I trial exploring the gene therapy in patients with alpha-1 antitrypsin deficiency is expected to start in Q1 2024.

Sep 23, 2023 - 20:00
FDA clears Krystal Biotech’s IND for Type 1 AATD treatment KB408
A Phase I trial exploring the gene therapy in patients with alpha-1 antitrypsin deficiency is expected to start in Q1 2024.
Read the original article

Tags:

Previous Article

STAT+: Travere kidney drug narrowly fails confirmatory trial following FDA approval

Next Article

Jazz Pharma’s Enrylaze wins European approval for AML and LBL

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

UK charities condemn continued drug shortages

UK charities condemn continued drug shortages

Apr 13, 2024

STAT+: Court allows Medicare drug price negotiation to proceed

STAT+: Court allows Medicare drug price negotiation to ...

Sep 30, 2023

Avenge Bio secures FDA orphan drug designation for mesothelioma therapy

Avenge Bio secures FDA orphan drug designation for meso...

Jun 17, 2023